Cymabay Therapeutics, Inc.

Diatex, Inc.

Ph Pharma Co., Ltd.

Brian K Roberts

Charles A McWherter

David Brian Karpf

Robert Louis Martin

Xueyan Wang

Yun-Jung Choi

Brian Edward Lavan

Gopal Chandra Saha

Charles A Mcwherter

Douglas Alan Lorenz

Rodney James Ketner

Sanjeev Satyal

Hoyoung Huh

Scott Savage

Treatment of NAFLD and NASH by therapy with MBX-8025 or an MBX-8025 salt.

Treatment of NAFLD and NASH

The invention relates to methods for treating chronic liver disease, in particular nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), with neutrophil elastase inhibitors. The invention further relates to pharmaceutical compositions comprising neutrophil elastase inhibitors.

Use of neutrophil elastase inhibitors in liver disease

Treatment for NAFLD and NASH

Disclosed herein are pharmaceutical compositions, methods and kits for lowering the serum uric acid level of a subject and for the treatment of a condition associated with elevated serum uric acid levels comprising administering a composition comprising a first urate-lowering agent and a second urate-lowering agent. In some aspects the first urate-lowering agent is (&#x2212;)-halofenate, (&#x2212;)-halofenic acid, or a pharmaceutically acceptable salts thereof. In some aspects the second urate-lowering agent is an inhibitor of uric acid production, a uricosuric agent, a uricase, or a pharmaceutically acceptable salt thereof.

Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent

This invention relates to the field of pharmaceutical chemistry and, more specifically, to pharmaceutical formulations as well as to intermediates used to prepare such formulations and to methods for manufacturing such formulations.

Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine

Methods of treating gout flares comprising administering a composition comprising a first urate-lowering agent are disclosed. In some aspects, the first urate-lowering agent is (&#x2212;)-halofenate, (&#x2212;)-halofenic acid, or a pharmaceutically acceptable salt thereof. Other aspects provide for methods of reducing the number, duration, frequency or intensity of gout flares experienced by a subject.

Methods for treating gout flares

Growing community of inventors

Palo Alto, CA, United States of America

Brian K Roberts